GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (MEX:GILD) » Definitions » Book Value per Share

Gilead Sciences (MEX:GILD) Book Value per Share : MXN291.94 (As of Sep. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Gilead Sciences Book Value per Share?

Gilead Sciences's book value per share for the quarter that ended in Sep. 2024 was MXN291.94.

During the past 12 months, Gilead Sciences's average Book Value Per Share Growth Rate was -17.10% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 8.10% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 1.40% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 7.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Gilead Sciences was 65.90% per year. The lowest was -13.50% per year. And the median was 19.60% per year.

Gilead Sciences's current price is MXN1843.00. Its book value per share for the quarter that ended in Sep. 2024 was MXN291.94. Hence, today's PB Ratio of Gilead Sciences is 6.31.

During the past 13 years, the highest P/B Ratio of Gilead Sciences was 12.10. The lowest was 3.45. And the median was 4.52.


Gilead Sciences Book Value per Share Historical Data

The historical data trend for Gilead Sciences's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Book Value per Share Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 335.56 288.74 344.67 332.07 311.04

Gilead Sciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 311.68 311.04 233.43 268.82 291.94

Competitive Comparison of Gilead Sciences's Book Value per Share

For the Drug Manufacturers - General subindustry, Gilead Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's PB Ratio distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's PB Ratio falls into.



Gilead Sciences Book Value per Share Calculation

Gilead Sciences's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(387,573-0)/1,246
=311.04

Gilead Sciences's Book Value Per Share for the quarter that ended in Sep. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(363,759-0)/1,246
=291.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Gilead Sciences  (MEX:GILD) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Gilead Sciences Book Value per Share Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).